Kasai Hiroi

カサイヒロイ | Kasai Hiroi

Affiliation and department：

Research field (1)： Medical equipment testing

Research keywords (1)： Clinical Research

Research theme for competitive and other funds (2)：

2016 - 2019 In-service training to promote becoming expert Clinical Research Coordinators
2012 - 2017 Perspectives on palliative care: Clinical practice guidelines and the issue of paient' preference and quality of life

Papers (17)：

Yukiko Mori, Osamu Kikuchi, Takahiro Horimatsu, Hiroki Hara, Shuichi Hironaka, Takashi Kojima, Ken Kato, Takahiro Tsushima, Ryu Ishihara, Kumi Mukai, et al. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus : official journal of the Japan Esophageal Society. 2022. 19. 3. 444-451
Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori E. Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, et al. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Research and Treatment. 2021. 188. 1. 117-131
Ryosuke Kurauchi, Hiroi Kasai, Tatsuya Ito. Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports. Frontiers in Bioengineering and Biotechnology. 2020. 8. 606606-606606
Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Research and Treatment. 2020. 180. 1. 135-146
R. Asada, Kenichi Yoshimura, Kayo Hattori, Yujiro Nonaka, H. Kasai, Shinobu Shimizu. A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan. Contemporary Clinical Trials Communications. 2019. 15. 100416-100416

ｍore...

MISC (82)：

ｍore...

Lectures and oral presentations (87)：

認定CRC試験の現状と今後の動向
(第41回日本臨床薬理学会学術集会 2020)
臨床試験の実施体制の構築手順とツールの理解
(AMED PM育成事業導入研修 2020)
医師主導治験スタディマネジャーのためのオペレーション支援ツール
(AMED PM育成事業導入研修 2020)
京都大学医学部附属病院における臨床研究法への対応ー研究者支援と医療機関としての研究管理ー
(国立病院機構近畿グループ「令和元年度臨床研究・治験研修」 2020)
京都大学医学部附属病院における臨床研究法への対応ー研究者支援と医療機関としての研究管理ー
(日本臨床試験学会第11回学術集会総会 in 東京シンポジウム「特定臨床研究の動向と今後の円滑な運営にむけての課題について」 2020)

ｍore...

Committee career (2)：

2018/04/01 - 2019/03/31 - -
2017/12/08 - The Japanese Society of Clinical Pharmacology and Therapeutics -

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page